The Clopidogrel in unstable angina to prevent recurrent events
To evaluate the efficacy and safety of clopidogrel when given with aspirin patients with non- ST-segment elevation acute coronary syndromes. Clopidogrel had beneficial, however, there was an increased risk of major bleeding. The findings of the CURE trial led to widespread use of clopidogrel in non -ST segment elevation ACS patients, modification of practice guidelines and regulatory approvals in many countries around the world. Clopidogrel has become an established therapy in these patients and one of the most commonly used drugs in ACS.
Randomized, controlled trial.
First co-primary outcome: the composite of death from CV causes, nonfatal MI, or stroke; Second co- primary outcome; the composite of the first primary outcome or refractory ischemia. Secondary outcomes: severe ischemia, heart failure, and the need for revascularization. Safety-related outcomes: bleeding complications, categorized as life-threatening, major or minor. All primary outcomes and life-threatening and major bleeding complications were adjudicated